Share Price and Basic Stock Data
Last Updated: January 17, 2026, 12:55 pm
| PEG Ratio | 275.92 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Aashka Hospitals Ltd operates in the Hospitals & Medical Services sector and has reported a current market price of ₹77.5, translating to a market capitalization of ₹181 Cr. The company has experienced significant fluctuations in revenue, with total sales standing at ₹18.94 Cr for the fiscal year ending March 2023, down from ₹39.73 Cr in March 2022. The latest reported sales for the trailing twelve months (TTM) are ₹20.72 Cr. Quarterly sales have shown a slight recovery, with ₹10.80 Cr reported in September 2023 and a projected ₹12.07 Cr for March 2024, indicating a potential upward trend in revenue. However, this is still below the peak sales of ₹40.69 Cr recorded in March 2021. The company’s operating profit margin (OPM) has fluctuated, currently at 20.21%, reflecting the challenges faced in maintaining profitability amid varying sales figures.
Profitability and Efficiency Metrics
Aashka Hospitals Ltd’s profitability metrics highlight a challenging operational environment. The company reported a net profit of ₹2.43 Cr, translating to a P/E ratio of 159, indicating that the market has high expectations relative to current earnings. The operating profit has varied significantly, with a low of -₹0.74 Cr in March 2022 and a recovery to ₹3.63 Cr in March 2024. The return on equity (ROE) stands at a modest 2.39%, while the return on capital employed (ROCE) is slightly better at 4.07%. The interest coverage ratio (ICR) of 4.41x suggests that the company can comfortably cover its interest expenses, which have decreased over the years, from ₹5.75 Cr in March 2019 to ₹1.72 Cr in March 2025. However, the operating profit margin has been volatile, indicating inefficiencies that could affect long-term profitability.
Balance Sheet Strength and Financial Ratios
Aashka Hospitals Ltd’s balance sheet reflects a cautious approach to debt management, with total borrowings reduced to ₹12.61 Cr from a high of ₹32.99 Cr in March 2019. The reserves have increased to ₹76.17 Cr, providing a cushion for future growth and stability. The current ratio stands at 1.29, indicating adequate liquidity to meet short-term obligations. However, the company’s total liabilities have decreased to ₹116.06 Cr, down from ₹129.12 Cr in March 2022, reflecting effective management of liabilities. The price-to-book value (P/BV) ratio is 2.40x, suggesting that the market values the company at a premium compared to its book value. The asset turnover ratio of 0.19% indicates that the company may not be utilizing its assets efficiently to generate revenue, which is a concern in the competitive healthcare sector.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Aashka Hospitals Ltd reveals a strong promoter presence, with promoters holding 61.34% of the shares as of September 2025. This stability may instill confidence among investors, as it indicates a commitment to the company’s long-term vision. The public shareholding stands at 38.68%, with the number of shareholders declining from 2,771 in September 2021 to 1,172 in September 2025. This reduction may raise concerns about investor interest and liquidity in the stock. The absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) could also reflect a lack of broader market confidence in the company’s prospects. The overall composition suggests that while promoter confidence remains high, broader investor sentiment may require improvement to enhance market engagement.
Outlook, Risks, and Final Insight
Aashka Hospitals Ltd faces several strengths and risks that will shape its future. On the positive side, a strong promoter holding and a reduced debt burden provide a solid foundation for potential growth. Additionally, the recovery in quarterly sales and improvements in operating profit margins suggest a possible turnaround. However, the company grapples with significant challenges, including inconsistent profitability and an inefficient asset utilization rate. The declining number of shareholders and lack of institutional interest could hinder market dynamics. Moving forward, the company needs to focus on enhancing operational efficiency and addressing investor confidence to capitalize on emerging opportunities in the healthcare sector. Aashka Hospitals Ltd’s ability to navigate these challenges will be critical in determining its trajectory in the competitive landscape of medical services.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 46.5 Cr. | 139 | 187/120 | 9.49 | 117 | 2.52 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 23.6 Cr. | 22.5 | 33.8/15.5 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 10.5 Cr. | 10.2 | 20.5/7.08 | 117 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 103 Cr. | 55.0 | 98.7/54.0 | 22.7 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 18.9 Cr. | 3.49 | 6.94/3.40 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 24,969.21 Cr | 666.72 | 87.64 | 93.18 | 0.34% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 24.82 | 28.42 | 11.32 | 11.54 | 7.41 | 10.80 | 12.07 | 12.36 | 10.28 | 10.44 |
| Expenses | 19.41 | 19.41 | 12.06 | 10.80 | 7.91 | 9.97 | 8.44 | 7.89 | 10.49 | 8.33 |
| Operating Profit | 5.41 | 9.01 | -0.74 | 0.74 | -0.50 | 0.83 | 3.63 | 4.47 | -0.21 | 2.11 |
| OPM % | 21.80% | 31.70% | -6.54% | 6.41% | -6.75% | 7.69% | 30.07% | 36.17% | -2.04% | 20.21% |
| Other Income | 0.04 | 0.04 | 0.09 | 0.06 | 3.06 | 2.61 | 1.61 | 0.07 | 4.20 | 0.90 |
| Interest | 1.43 | 1.43 | 1.23 | -0.17 | 3.17 | 1.46 | 1.45 | 1.02 | 0.70 | 0.63 |
| Depreciation | 1.45 | 1.45 | 1.44 | 1.44 | 1.49 | 1.47 | 1.45 | 1.58 | 1.37 | 1.46 |
| Profit before tax | 2.57 | 6.17 | -3.32 | -0.47 | -2.10 | 0.51 | 2.34 | 1.94 | 1.92 | 0.92 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 17.65% | 17.09% | 16.49% | 14.58% | 15.22% |
| Net Profit | 2.57 | 6.17 | -3.33 | -0.47 | -2.10 | 0.42 | 1.93 | 1.62 | 1.65 | 0.78 |
| EPS in Rs | 1.43 | 2.64 | -1.42 | -0.20 | -0.90 | 0.18 | 0.82 | 0.69 | 0.71 | 0.33 |
Last Updated: December 28, 2025, 10:35 am
Below is a detailed analysis of the quarterly data for Aashka Hospitals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 10.44 Cr.. The value appears strong and on an upward trend. It has increased from 10.28 Cr. (Mar 2025) to 10.44 Cr., marking an increase of 0.16 Cr..
- For Expenses, as of Sep 2025, the value is 8.33 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 10.49 Cr. (Mar 2025) to 8.33 Cr., marking a decrease of 2.16 Cr..
- For Operating Profit, as of Sep 2025, the value is 2.11 Cr.. The value appears strong and on an upward trend. It has increased from -0.21 Cr. (Mar 2025) to 2.11 Cr., marking an increase of 2.32 Cr..
- For OPM %, as of Sep 2025, the value is 20.21%. The value appears strong and on an upward trend. It has increased from -2.04% (Mar 2025) to 20.21%, marking an increase of 22.25%.
- For Other Income, as of Sep 2025, the value is 0.90 Cr.. The value appears to be declining and may need further review. It has decreased from 4.20 Cr. (Mar 2025) to 0.90 Cr., marking a decrease of 3.30 Cr..
- For Interest, as of Sep 2025, the value is 0.63 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.70 Cr. (Mar 2025) to 0.63 Cr., marking a decrease of 0.07 Cr..
- For Depreciation, as of Sep 2025, the value is 1.46 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.37 Cr. (Mar 2025) to 1.46 Cr., marking an increase of 0.09 Cr..
- For Profit before tax, as of Sep 2025, the value is 0.92 Cr.. The value appears to be declining and may need further review. It has decreased from 1.92 Cr. (Mar 2025) to 0.92 Cr., marking a decrease of 1.00 Cr..
- For Tax %, as of Sep 2025, the value is 15.22%. The value appears to be increasing, which may not be favorable. It has increased from 14.58% (Mar 2025) to 15.22%, marking an increase of 0.64%.
- For Net Profit, as of Sep 2025, the value is 0.78 Cr.. The value appears to be declining and may need further review. It has decreased from 1.65 Cr. (Mar 2025) to 0.78 Cr., marking a decrease of 0.87 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.33. The value appears to be declining and may need further review. It has decreased from 0.71 (Mar 2025) to 0.33, marking a decrease of 0.38.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:21 am
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 27.67 | 27.23 | 40.69 | 39.73 | 18.94 | 22.87 | 22.65 | 20.72 |
| Expenses | 18.08 | 18.41 | 30.72 | 31.16 | 18.59 | 18.41 | 18.37 | 18.82 |
| Operating Profit | 9.59 | 8.82 | 9.97 | 8.57 | 0.35 | 4.46 | 4.28 | 1.90 |
| OPM % | 34.66% | 32.39% | 24.50% | 21.57% | 1.85% | 19.50% | 18.90% | 9.17% |
| Other Income | 0.06 | 0.02 | 0.00 | 0.13 | 3.10 | 4.21 | 4.26 | 5.10 |
| Interest | 5.75 | 4.90 | 3.25 | 2.96 | 3.09 | 2.91 | 1.72 | 1.33 |
| Depreciation | 2.54 | 2.56 | 2.61 | 2.90 | 2.93 | 2.92 | 2.95 | 2.83 |
| Profit before tax | 1.36 | 1.38 | 4.11 | 2.84 | -2.57 | 2.84 | 3.87 | 2.84 |
| Tax % | 0.00% | 0.00% | 0.00% | 16.55% | 0.00% | 17.25% | 15.50% | |
| Net Profit | 1.36 | 1.38 | 4.11 | 2.37 | -2.57 | 2.36 | 3.27 | 2.43 |
| EPS in Rs | 0.76 | 0.77 | 2.28 | 1.01 | -1.10 | 1.01 | 1.40 | 1.04 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 1.47% | 197.83% | -42.34% | -208.44% | 191.83% | 38.56% |
| Change in YoY Net Profit Growth (%) | 0.00% | 196.36% | -240.16% | -166.10% | 400.27% | -153.27% |
Aashka Hospitals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2019-2020 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -4% |
| 3 Years: | -17% |
| TTM: | -1% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 11% |
| 3 Years: | 0% |
| TTM: | -1% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 25% |
| 1 Year: | -27% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 2% |
| 3 Years: | 1% |
| Last Year: | 2% |
Last Updated: September 5, 2025, 2:01 pm
Balance Sheet
Last Updated: September 10, 2025, 2:52 pm
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 17.16 | 17.91 | 18.00 | 23.37 | 23.37 | 23.37 | 23.37 |
| Reserves | -1.80 | 6.28 | 11.25 | 73.20 | 70.55 | 72.91 | 76.17 |
| Borrowings | 32.99 | 30.92 | 27.87 | 28.21 | 29.19 | 20.39 | 12.61 |
| Other Liabilities | 5.71 | 4.93 | 7.96 | 4.34 | 4.92 | 4.78 | 3.91 |
| Total Liabilities | 54.06 | 60.04 | 65.08 | 129.12 | 128.03 | 121.45 | 116.06 |
| Fixed Assets | 46.36 | 44.12 | 49.49 | 48.46 | 45.47 | 42.78 | 40.79 |
| CWIP | 0.08 | 0.00 | 0.00 | 0.00 | 0.05 | 0.45 | 0.88 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 7.62 | 15.92 | 15.59 | 80.66 | 82.51 | 78.22 | 74.39 |
| Total Assets | 54.06 | 60.04 | 65.08 | 129.12 | 128.03 | 121.45 | 116.06 |
Below is a detailed analysis of the balance sheet data for Aashka Hospitals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 23.37 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 23.37 Cr..
- For Reserves, as of Mar 2025, the value is 76.17 Cr.. The value appears strong and on an upward trend. It has increased from 72.91 Cr. (Mar 2024) to 76.17 Cr., marking an increase of 3.26 Cr..
- For Borrowings, as of Mar 2025, the value is 12.61 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 20.39 Cr. (Mar 2024) to 12.61 Cr., marking a decrease of 7.78 Cr..
- For Other Liabilities, as of Mar 2025, the value is 3.91 Cr.. The value appears to be improving (decreasing). It has decreased from 4.78 Cr. (Mar 2024) to 3.91 Cr., marking a decrease of 0.87 Cr..
- For Total Liabilities, as of Mar 2025, the value is 116.06 Cr.. The value appears to be improving (decreasing). It has decreased from 121.45 Cr. (Mar 2024) to 116.06 Cr., marking a decrease of 5.39 Cr..
- For Fixed Assets, as of Mar 2025, the value is 40.79 Cr.. The value appears to be declining and may need further review. It has decreased from 42.78 Cr. (Mar 2024) to 40.79 Cr., marking a decrease of 1.99 Cr..
- For CWIP, as of Mar 2025, the value is 0.88 Cr.. The value appears strong and on an upward trend. It has increased from 0.45 Cr. (Mar 2024) to 0.88 Cr., marking an increase of 0.43 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 74.39 Cr.. The value appears to be declining and may need further review. It has decreased from 78.22 Cr. (Mar 2024) to 74.39 Cr., marking a decrease of 3.83 Cr..
- For Total Assets, as of Mar 2025, the value is 116.06 Cr.. The value appears to be declining and may need further review. It has decreased from 121.45 Cr. (Mar 2024) to 116.06 Cr., marking a decrease of 5.39 Cr..
Notably, the Reserves (76.17 Cr.) exceed the Borrowings (12.61 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Free Cash Flow | -23.40 | -22.10 | -17.90 | -19.64 | -28.84 | -15.93 | -8.33 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 45.64 | 90.48 | 65.66 | 71.84 | 132.20 | 76.93 | 76.06 |
| Inventory Days | 51.35 | 66.55 | 30.28 | 34.97 | 56.59 | 48.75 | 58.63 |
| Days Payable | 296.91 | 247.49 | 241.09 | 101.11 | 365.00 | 263.54 | 130.46 |
| Cash Conversion Cycle | -199.92 | -90.46 | -145.15 | 5.71 | -176.21 | -137.86 | 4.23 |
| Working Capital Days | -93.26 | 19.57 | -38.48 | -34.27 | -126.42 | -123.21 | 3.38 |
| ROCE % | 12.14% | 13.12% | 6.38% | 0.42% | 4.80% | 4.07% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.40 | 1.01 | -1.10 | 1.12 | 2.29 |
| Diluted EPS (Rs.) | 1.40 | 1.01 | -1.10 | 1.12 | 2.29 |
| Cash EPS (Rs.) | 2.66 | 2.26 | 0.15 | 2.25 | 3.73 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 42.60 | 41.20 | 40.19 | 41.32 | 16.25 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 42.60 | 41.20 | 40.19 | 41.32 | 16.25 |
| Revenue From Operations / Share (Rs.) | 9.69 | 9.79 | 8.11 | 17.00 | 22.60 |
| PBDIT / Share (Rs.) | 3.26 | 3.71 | 1.44 | 3.59 | 5.51 |
| PBIT / Share (Rs.) | 2.00 | 2.46 | 0.18 | 2.35 | 4.06 |
| PBT / Share (Rs.) | 1.66 | 1.22 | -1.10 | 1.21 | 2.29 |
| Net Profit / Share (Rs.) | 1.40 | 1.01 | -1.10 | 1.01 | 2.29 |
| PBDIT Margin (%) | 33.62 | 37.92 | 17.75 | 21.12 | 24.36 |
| PBIT Margin (%) | 20.61 | 25.17 | 2.27 | 13.82 | 17.96 |
| PBT Margin (%) | 17.08 | 12.44 | -13.56 | 7.14 | 10.11 |
| Net Profit Margin (%) | 14.42 | 10.30 | -13.56 | 5.95 | 10.11 |
| Return on Networth / Equity (%) | 3.28 | 2.44 | -2.73 | 2.44 | 14.06 |
| Return on Capital Employeed (%) | 4.39 | 5.47 | 0.38 | 4.81 | 14.60 |
| Return On Assets (%) | 2.81 | 1.94 | -2.00 | 1.83 | 6.32 |
| Long Term Debt / Equity (X) | 0.06 | 0.08 | 0.16 | 0.17 | 0.68 |
| Total Debt / Equity (X) | 0.12 | 0.21 | 0.31 | 0.29 | 0.74 |
| Asset Turnover Ratio (%) | 0.19 | 0.18 | 0.14 | 0.40 | 0.65 |
| Current Ratio (X) | 1.29 | 0.64 | 0.79 | 0.82 | 1.01 |
| Quick Ratio (X) | 1.25 | 0.62 | 0.77 | 0.78 | 0.97 |
| Inventory Turnover Ratio (X) | 58.72 | 0.00 | 0.00 | 10.54 | 10.90 |
| Interest Coverage Ratio (X) | 4.41 | 2.98 | 1.12 | 3.16 | 3.10 |
| Interest Coverage Ratio (Post Tax) (X) | 2.36 | 1.81 | 0.14 | 1.89 | 2.29 |
| Enterprise Value (Cr.) | 248.61 | 199.58 | 124.69 | 144.22 | 0.00 |
| EV / Net Operating Revenue (X) | 10.98 | 8.73 | 6.58 | 3.63 | 0.00 |
| EV / EBITDA (X) | 32.65 | 23.00 | 37.06 | 17.18 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 10.54 | 7.92 | 5.20 | 2.95 | 0.00 |
| Price / BV (X) | 2.40 | 1.88 | 1.05 | 1.21 | 0.00 |
| Price / Net Operating Revenue (X) | 10.54 | 7.92 | 5.20 | 2.95 | 0.00 |
| EarningsYield | 0.01 | 0.01 | -0.02 | 0.02 | 0.00 |
After reviewing the key financial ratios for Aashka Hospitals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 1.40. This value is below the healthy minimum of 5. It has increased from 1.01 (Mar 24) to 1.40, marking an increase of 0.39.
- For Diluted EPS (Rs.), as of Mar 25, the value is 1.40. This value is below the healthy minimum of 5. It has increased from 1.01 (Mar 24) to 1.40, marking an increase of 0.39.
- For Cash EPS (Rs.), as of Mar 25, the value is 2.66. This value is below the healthy minimum of 3. It has increased from 2.26 (Mar 24) to 2.66, marking an increase of 0.40.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 42.60. It has increased from 41.20 (Mar 24) to 42.60, marking an increase of 1.40.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 42.60. It has increased from 41.20 (Mar 24) to 42.60, marking an increase of 1.40.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 9.69. It has decreased from 9.79 (Mar 24) to 9.69, marking a decrease of 0.10.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 3.26. This value is within the healthy range. It has decreased from 3.71 (Mar 24) to 3.26, marking a decrease of 0.45.
- For PBIT / Share (Rs.), as of Mar 25, the value is 2.00. This value is within the healthy range. It has decreased from 2.46 (Mar 24) to 2.00, marking a decrease of 0.46.
- For PBT / Share (Rs.), as of Mar 25, the value is 1.66. This value is within the healthy range. It has increased from 1.22 (Mar 24) to 1.66, marking an increase of 0.44.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 1.40. This value is below the healthy minimum of 2. It has increased from 1.01 (Mar 24) to 1.40, marking an increase of 0.39.
- For PBDIT Margin (%), as of Mar 25, the value is 33.62. This value is within the healthy range. It has decreased from 37.92 (Mar 24) to 33.62, marking a decrease of 4.30.
- For PBIT Margin (%), as of Mar 25, the value is 20.61. This value exceeds the healthy maximum of 20. It has decreased from 25.17 (Mar 24) to 20.61, marking a decrease of 4.56.
- For PBT Margin (%), as of Mar 25, the value is 17.08. This value is within the healthy range. It has increased from 12.44 (Mar 24) to 17.08, marking an increase of 4.64.
- For Net Profit Margin (%), as of Mar 25, the value is 14.42. This value exceeds the healthy maximum of 10. It has increased from 10.30 (Mar 24) to 14.42, marking an increase of 4.12.
- For Return on Networth / Equity (%), as of Mar 25, the value is 3.28. This value is below the healthy minimum of 15. It has increased from 2.44 (Mar 24) to 3.28, marking an increase of 0.84.
- For Return on Capital Employeed (%), as of Mar 25, the value is 4.39. This value is below the healthy minimum of 10. It has decreased from 5.47 (Mar 24) to 4.39, marking a decrease of 1.08.
- For Return On Assets (%), as of Mar 25, the value is 2.81. This value is below the healthy minimum of 5. It has increased from 1.94 (Mar 24) to 2.81, marking an increase of 0.87.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 0.2. It has decreased from 0.08 (Mar 24) to 0.06, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.12. This value is within the healthy range. It has decreased from 0.21 (Mar 24) to 0.12, marking a decrease of 0.09.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.19. It has increased from 0.18 (Mar 24) to 0.19, marking an increase of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 1.29. This value is below the healthy minimum of 1.5. It has increased from 0.64 (Mar 24) to 1.29, marking an increase of 0.65.
- For Quick Ratio (X), as of Mar 25, the value is 1.25. This value is within the healthy range. It has increased from 0.62 (Mar 24) to 1.25, marking an increase of 0.63.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 58.72. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 58.72, marking an increase of 58.72.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 4.41. This value is within the healthy range. It has increased from 2.98 (Mar 24) to 4.41, marking an increase of 1.43.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.36. This value is below the healthy minimum of 3. It has increased from 1.81 (Mar 24) to 2.36, marking an increase of 0.55.
- For Enterprise Value (Cr.), as of Mar 25, the value is 248.61. It has increased from 199.58 (Mar 24) to 248.61, marking an increase of 49.03.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 10.98. This value exceeds the healthy maximum of 3. It has increased from 8.73 (Mar 24) to 10.98, marking an increase of 2.25.
- For EV / EBITDA (X), as of Mar 25, the value is 32.65. This value exceeds the healthy maximum of 15. It has increased from 23.00 (Mar 24) to 32.65, marking an increase of 9.65.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 10.54. This value exceeds the healthy maximum of 3. It has increased from 7.92 (Mar 24) to 10.54, marking an increase of 2.62.
- For Price / BV (X), as of Mar 25, the value is 2.40. This value is within the healthy range. It has increased from 1.88 (Mar 24) to 2.40, marking an increase of 0.52.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 10.54. This value exceeds the healthy maximum of 3. It has increased from 7.92 (Mar 24) to 10.54, marking an increase of 2.62.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Aashka Hospitals Ltd:
- Net Profit Margin: 14.42%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 4.39% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 3.28% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.36
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.25
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 162 (Industry average Stock P/E: 87.64)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.12
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 14.42%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | Between Sargasan & Reliance Cross Road, Sargasan, Gandhinagar Gujarat 382421 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Bipinchandra D Shah | Chairman & Managing Director |
| Mrs. Shreyarthi B Shah | Director |
| Mr. Umang A Shah | Independent Director |
| Mr. Jigar K Trivedi | Independent Director |
FAQ
What is the intrinsic value of Aashka Hospitals Ltd?
Aashka Hospitals Ltd's intrinsic value (as of 21 January 2026) is ₹135.06 which is 70.96% higher the current market price of ₹79.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹185 Cr. market cap, FY2025-2026 high/low of ₹120/65.1, reserves of ₹76.17 Cr, and liabilities of ₹116.06 Cr.
What is the Market Cap of Aashka Hospitals Ltd?
The Market Cap of Aashka Hospitals Ltd is 185 Cr..
What is the current Stock Price of Aashka Hospitals Ltd as on 21 January 2026?
The current stock price of Aashka Hospitals Ltd as on 21 January 2026 is ₹79.0.
What is the High / Low of Aashka Hospitals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Aashka Hospitals Ltd stocks is ₹120/65.1.
What is the Stock P/E of Aashka Hospitals Ltd?
The Stock P/E of Aashka Hospitals Ltd is 162.
What is the Book Value of Aashka Hospitals Ltd?
The Book Value of Aashka Hospitals Ltd is 42.5.
What is the Dividend Yield of Aashka Hospitals Ltd?
The Dividend Yield of Aashka Hospitals Ltd is 0.00 %.
What is the ROCE of Aashka Hospitals Ltd?
The ROCE of Aashka Hospitals Ltd is 4.07 %.
What is the ROE of Aashka Hospitals Ltd?
The ROE of Aashka Hospitals Ltd is 2.39 %.
What is the Face Value of Aashka Hospitals Ltd?
The Face Value of Aashka Hospitals Ltd is 10.0.